ENPH vs. MRNA
ENPH (Enphase Energy, Inc.) and MRNA (Moderna, Inc.) are both stocks. ENPH operates in Solar (Technology), while MRNA operates in Biotechnology (Healthcare). Over the past 5 years, ENPH returned -12.68%/yr vs -24.19%/yr for MRNA. At a 0.27 correlation, their price movements are largely independent.
Performance
ENPH vs. MRNA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ENPH achieves a 113.39% return, which is significantly higher than MRNA's 74.94% return.
ENPH
- 1D
- -0.91%
- 1M
- 89.87%
- YTD
- 113.39%
- 6M
- 122.33%
- 1Y
- 58.46%
- 3Y*
- -27.93%
- 5Y*
- -12.68%
- 10Y*
- 40.45%
MRNA
- 1D
- 5.16%
- 1M
- 10.45%
- YTD
- 74.94%
- 6M
- 102.39%
- 1Y
- 89.18%
- 3Y*
- -26.31%
- 5Y*
- -24.19%
- 10Y*
- —
ENPH vs. MRNA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
ENPH Enphase Energy, Inc. | 113.39% | -53.33% | -48.02% | -50.13% | 44.83% | 4.26% | 571.53% | 452.43% | -16.73% |
MRNA Moderna, Inc. | 74.94% | -29.08% | -58.19% | -44.63% | -29.28% | 143.11% | 434.10% | 28.09% | -17.90% |
Correlation
The correlation between ENPH and MRNA is 0.31, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.31 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.34 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.34 |
Correlation (All Time) Calculated using the full available price history since Dec 10, 2018 | 0.27 |
Fundamentals
ENPH:
$8.98B
MRNA:
$20.38B
ENPH:
$0.92
MRNA:
-$8.16
ENPH:
6.51
MRNA:
9.07
ENPH:
8.15
MRNA:
2.75
ENPH:
$1.40B
MRNA:
$2.23B
ENPH:
$619.16M
MRNA:
-$309.00M
ENPH:
$189.48M
MRNA:
-$3.02B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ENPH vs. MRNA — Risk / Return Rank
ENPH
MRNA
ENPH vs. MRNA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Enphase Energy, Inc. (ENPH) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ENPH | MRNA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.70 | ||
| Sortino ratioReturn per unit of downside risk | -0.65 | ||
| Omega ratioGain probability vs. loss probability | 1.20 | 1.25 | -0.05 |
| Calmar ratioReturn relative to maximum drawdown | 1.36 | 2.53 | -1.16 |
| Martin ratioReturn relative to average drawdown | 2.46 | 5.00 | -2.53 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| ENPH | MRNA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.70 | 1.40 | -0.70 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.18 | -0.37 | +0.18 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.52 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.21 | 0.20 | +0.01 |
Drawdowns
ENPH vs. MRNA - Drawdown Comparison
The maximum ENPH drawdown since its inception was -95.97%, roughly equal to the maximum MRNA drawdown of -95.38%. Use the drawdown chart below to compare losses from any high point for ENPH and MRNA.
Loading charts...
Drawdown Indicators
| ENPH | MRNA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.97% | -95.38% | -0.59% |
Max Drawdown (1Y)Largest decline over 1 year | -43.13% | -35.51% | -7.62% |
Max Drawdown (3Y)Largest decline over 3 years | -86.23% | -86.58% | +0.35% |
Max Drawdown (5Y)Largest decline over 5 years | -92.23% | -95.38% | +3.15% |
Max Drawdown (10Y)Largest decline over 10 years | -92.23% | — | — |
Current DrawdownCurrent decline from peak | -79.65% | -89.35% | +9.70% |
Average DrawdownAverage peak-to-trough decline | -50.53% | -56.66% | +6.13% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.79% | 17.90% | +5.89% |
Volatility
ENPH vs. MRNA - Volatility Comparison
Enphase Energy, Inc. (ENPH) has a higher volatility of 32.51% compared to Moderna, Inc. (MRNA) at 18.65%. This indicates that ENPH's price experiences larger fluctuations and is considered to be riskier than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ENPH | MRNA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 32.51% | 18.65% | +13.86% |
Volatility (6M)Calculated over the trailing 6-month period | 62.14% | 48.15% | +13.99% |
Volatility (1Y)Calculated over the trailing 1-year period | 84.42% | 64.07% | +20.35% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 69.64% | 66.39% | +3.25% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 78.13% | 71.92% | +6.21% |
Dividends
ENPH vs. MRNA - Dividend Comparison
Neither ENPH nor MRNA has paid dividends to shareholders.
Financials
ENPH vs. MRNA - Financials Comparison
This section allows you to compare key financial metrics between Enphase Energy, Inc. and Moderna, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ENPH and MRNA have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ENPH has higher volatility (32.51%) compared to MRNA (18.65%). In terms of maximum drawdown, ENPH dropped -95.97% vs MRNA's -95.38%.
MRNA currently has the higher Sharpe Ratio (1.40 vs 0.70), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ENPH and MRNA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer